Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 113 trials | ||||||
| Phase 1 | NCT02058641 | Feb → Aug 2014 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02000804 | Oct 2013 → Jan 2014 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01873339 | Jun → Sep 2013 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01852565 | May → Sep 2013 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01751074 | Dec 2012 → Mar 2013 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01711723 | Oct 2012 → Mar 2013 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01154114 | Jul → Oct 2010 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00743860 | Sep → Dec 2008 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00704431 | May → Oct 2008 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00622830 | Jan → Mar 2008 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00551317 | Jul → Sep 2007 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00411073 | Dec 2006 → ? | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00368576 | Aug 2006 → Oct 2007 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01506895 | Feb 2012 → Feb 2013 | diabetic macular edema | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00734032 | Aug 2008 → Jan 2009 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00268996 | Nov 2005 → Aug 2007 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00269048 | Nov 2005 → Sep 2006 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01916720 | Jan → Jul 2003 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01067339 | Feb 2010 → Nov 2015 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 3 | NCT01000727 | Dec 2009 → Apr 2014 | acute coronary syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00799903 | Dec 2008 → Oct 2013 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darapladib | “BACKGROUND: The aim of this study was to assess the effects of darapladib, a selective oral investigational lipoprotein-associated phospholipase A2 inhibitor, on both plasma...” PMID 24586490 ↗ Feb 201417“This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk.” PMID 18436114 ↗ Apr 2008 “SB-480848 (Darapladib)” NCT00622830 ↗ |
| Known as | SB-480848 | “Darapladib (SB-480848) is a novel, selective, orally active inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2) currently under clinical development by...” NCT01852565 ↗13“SB-480848 (darapladib) is a novel selective and orally active inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) being developed by GlaxoSmithKline (GSK) for the...” NCT02000804 ↗ “A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and Its Metabolites in Healthy Volunteers.” NCT00743860 ↗ “Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy” NCT01916720 ↗ “A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment” NCT01711723 ↗ “An Open-label, Single-sequence Study to Evaluate the Potential CYP 3A4 Pharmacokinetic Interaction of Darapladib (SB-480848) in Healthy Subjects” NCT01873339 ↗ “The subjects will be administered 40 mg oral doses of darapladib (SB-480848) enteric-coated tablets daily for 10 consecutive days.” NCT01154114 ↗ “Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart” NCT00411073 ↗ “SB-480848 (darapladib)” NCT00704431 ↗ “Darapladib (SB480848)” NCT00551317 ↗ |
| Action | Inhibit | “Novel Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Inhibitor SB-480848” NCT00268996 ↗1“LDL-associated phospholipase A2 inhibitor” CHEMBL204021 ↗ |
| Modality | Small molecule | — CHEMBL204021 ↗ |
| Route | Oral | “Coronary heart disease (CHD) and CHD-risk equivalent patients (n = 959) receiving atorvastatin (20 or 80 mg) were randomized to oral darapladib 40 mg, 80 mg, 160 mg, or placebo...” PMID 18436114 ↗ Apr 2008 |
| Target | PLA2G7 | “LDL-associated phospholipase A2 inhibitor” CHEMBL204021 ↗ |